On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT – Research Report) and Crispr ...

Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. securities between June 30, 2024 and January ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of development in ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

U.S. Treasuries pared some of Wednesday's weakness that was prompted by above-consensus inflation data. The 2- and 10-year Treasury yields fell 3 basis points to 4.338% and 4.606%, respectively, ...

Millrose Properties, a land bank spun off by the home-building company, shows that investing in spinoffs isn’t necessarily a walk in the park.

Gilead Sciences reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $7.56 billion which beat the analyst consensus estimate ...